Company news
Unicycive Therapeutics, Inc. news in 2024
Unicycive Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.
Unicycive Therapeutics Announces Publication of Oxylanthanum Carbonate (OLC) Positive Bioequivalence Data in Clinical Therapeutics
December 16, 2024
Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference
November 20, 2024
Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
November 10, 2024
Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024
October 27, 2024
Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024
October 15, 2024
Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024
October 13, 2024
Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers
October 8, 2024
Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024
September 23, 2024
Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024
September 15, 2024
Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 4, 2024
Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
September 2, 2024
Unicycive Therapeutics to Present Three Posters at the American Society of Nephrology (ASN) Kidney Week 2024
August 25, 2024
Unicycive Announces Second Quarter 2024 Financial Results and Provides Business Update
August 13, 2024
Unicycive Therapeutics Granted Patent on UNI-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (USPTO)
July 16, 2024
Unicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
July 10, 2024
Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate (OLC)
July 9, 2024
Unicycive Therapeutics Joins Russell Microcap® Index
June 30, 2024
Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial
June 24, 2024
Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress
May 27, 2024
Unicycive Therapeutics to Participate in a Fireside Chat at the Lytham Partners Spring 2024 Investor Conference
May 22, 2024
Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical Meeting
May 14, 2024
Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update
May 12, 2024
Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
April 9, 2024
Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update
March 27, 2024
Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress
March 24, 2024
Unicycive Announces $50 Million Private Placement
March 13, 2024
Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference
March 12, 2024
Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)
March 6, 2024
Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients
March 3, 2024
Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting
February 13, 2024
Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference
January 28, 2024
Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones
January 22, 2024
Decks in 2024
- Technical Presentation (June 2024)
Technical · 29 slides · Jun 25, 2024